Virbac: sales up 8% in Q3

(CercleFinance.com) - Virbac has posted Q3 2024 sales of E339.
2m, up 7.7%, notably due to recent external growth operations, which contributed +6.5 points.

The animal health group's LFL sales growth reached +3.4%, penalised by an unfavourable comparison basis and with contrasting organic growth dynamics depending on the region.

For FY 2024, Virbac confirms its targets for LFL sales growth of 7% to 9%, with adjusted operating income before non-recurring items of around 16%, vs. 15.1% in 2023.


Copyright (c) 2024 CercleFinance.com. All rights reserved.